Go offline with the Player FM app!
Clinical Applications of Biomarkers and Large-Scale Collaborative Research with Charles Adler
Manage episode 465468415 series 2456444
Substantial research has focused on identifying biomarkers for the diagnosis of Parkinson's disease (PD) as well as monitoring progression of the disease. In developing these biomarkers, it is critical for scientists to consider how the biomarkers will ultimately be used in the clinic and in clinical trials research. In this interview, Dr. Charles (Chuck) Adler shares his perspectives on how biomarkers are currently being used in clinical and research contexts, and what it would take for him to use them more often in clinical practice. He also discusses how groundbreaking collaborative research studies, including the Arizona Study of Aging and Neurodegenerative Disorders and the Parkinson's Progression Markers Initiative (PPMI), are having major impacts on the field. Chuck is Consultant and Professor of Neurology in the Department of Neurology and The Wayne and Kathryn Preisel Professor of Neuroscience Research at the Mayo Clinic Alix School of Medicine at the Mayo Clinic in Arizona.
Mentioned in this episode:
From now through December 2, you can help accelerate Parkinson’s research. This Giving Tuesday, all donations to The Michael J. Fox Foundation will be matched up to $4 million, which means your impact will be doubled. Visit michaeljfox.org/givetoresearch to be part of the cure.
This podcast episode was part of a limited series created by The Michael J. Fox Foundation in 2023 and 2024 for clinicians and researchers in our audience. These episodes provide a deeper dive into exciting new scientific research in Parkinson’s disease, as well as innovative tools and valuable resources, through conversations with a variety of experts in the field. We hope you enjoy the conversation.
256 episodes
Manage episode 465468415 series 2456444
Substantial research has focused on identifying biomarkers for the diagnosis of Parkinson's disease (PD) as well as monitoring progression of the disease. In developing these biomarkers, it is critical for scientists to consider how the biomarkers will ultimately be used in the clinic and in clinical trials research. In this interview, Dr. Charles (Chuck) Adler shares his perspectives on how biomarkers are currently being used in clinical and research contexts, and what it would take for him to use them more often in clinical practice. He also discusses how groundbreaking collaborative research studies, including the Arizona Study of Aging and Neurodegenerative Disorders and the Parkinson's Progression Markers Initiative (PPMI), are having major impacts on the field. Chuck is Consultant and Professor of Neurology in the Department of Neurology and The Wayne and Kathryn Preisel Professor of Neuroscience Research at the Mayo Clinic Alix School of Medicine at the Mayo Clinic in Arizona.
Mentioned in this episode:
From now through December 2, you can help accelerate Parkinson’s research. This Giving Tuesday, all donations to The Michael J. Fox Foundation will be matched up to $4 million, which means your impact will be doubled. Visit michaeljfox.org/givetoresearch to be part of the cure.
This podcast episode was part of a limited series created by The Michael J. Fox Foundation in 2023 and 2024 for clinicians and researchers in our audience. These episodes provide a deeper dive into exciting new scientific research in Parkinson’s disease, as well as innovative tools and valuable resources, through conversations with a variety of experts in the field. We hope you enjoy the conversation.
256 episodes
كل الحلقات
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.